

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sang-Nyun KIM et al.

Appl. No: Unassigned

Filed: February 12, 2002

For: USE OF [γ -HYDROXY-N-METHYL-
LEUCINE⁹] CYCLOSPORIN A FOR
HAIR GROWTH

Art Unit: Unassigned

Examiner: Unassigned

Atty. Docket No: 36470-178260

Customer No:



26694

PATENT TRADEMARK OFFICE

JC929 U.S. PTO
10/073021
02/12/02

Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application. One copy of each of the listed documents is submitted herewith.

The relevance of the documents is described in the present specification.


The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the documents and make them of record.

Please charge any necessary fee or credit any overpayment in connection with this
Information Disclosure Statement to Deposit Account No. 22-0261.

Date: Feb. 12, 2002

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Richard D. Schmidt". The signature is written in dark ink and is positioned above the printed name.

Richard D. Schmidt

Registration No. 31,301

VENABLE

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 962-4800

Telefax: (202) 962-8300

+

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible][illegible]

VENABLE
ATTORNEYS AT LAW

10/073021
02/12/02

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Unassigned
				Filing Date	February 12, 2002
				First Named Inventor	Sang-Nyun KIM et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	36470-178260
Sheet	2	of	2		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A9	GUPTA et al., "Oral Cyclosporine for the Treatment of Alopecia Areata", J. Am. Acad. Dermatol Vol. 22(2):242-250, (1990)	
	A10	GILHAR et al., " Topical Cyclosporine in Male Pattern Alopecia", J. Am. Acad. Dermatol, Vol. 22, pp. 251-253, (1990)	
	A11	LUTZ, "Effects of Cyclosporin A On Hair", Skin Pharmacol, Vol. 7, pp. 101-104, (1994)	
	A12	MAURER et al., "Hair Growth Modulation by Topical Immunophilin Ligands", American Journal of Pathology, American Society for Investigative Pathology, Vol. 150(4):1433-1441, (1997)	
	A13	FREED et al., "In Vitro Immunosuppressive Properties of Cyclosporine Metabolites", Transplantation, The Williams & Wilkins Co., Vol. 43(1):123-127, (1987)	
	A14	COPELAND et al., "Immunosuppressive Activity of Cyclosporine Metabolites Compared And Characterized By Mass Spectroscopy And Nuclear Magnetic Resonance", Clinical Chemistry, Vol. 36(2):225-229, (1990)	
	A15	RYFFEL et al., "Biologic Significance of Cyclosporine Metabolites", Metabolites of Cyclosporine, Transplantation Proceedings, Vol. XX(2):575-584, (1988)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

VENABLE
ATTORNEYS AT LAW